TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33185896
Drug: Indomethacin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (1.2 mg kg–1 oral dose)
Study: 34622548
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (3, 7 or 14 mg)
Study: 34622548
Drug: Comparator (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (placebo or once‐daily subcutaneous liraglutide 0.9 mg [PIONEER 9]; once‐weekly subcutaneous dulaglutide 0.75 mg [PIONEER 10])
Study: 36030327
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron followed by daily doses for five days
Study: 33652093
Drug: Hospice representatives
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hospice representatives reporting on medication shortages
Study: 33652093
Drug: Hospice representatives
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hospice representatives reporting on missing opioid medications
Study: 35588970
Drug: Rapid phenotypic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid phenotypic antibiotic susceptibility testing (AST) with antimicrobial stewardship programmes (ASP)
Study: 34914696
Drug: 3HP facilitated
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP facilitated directly observed therapy (DOT)
Study: 34914696
Drug: 3HP facilitated
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP facilitated self-administered therapy (SAT)
Study: 35177302
Drug: mRNA-1273 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (100 µg, two doses, intramuscular injections 28 days apart)
Study: 33766713
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with CCTα biomarker
Study: 33766713
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with CCTα and emmprin biomarkers
Study: 33766713
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with CCTα, survivin, or BCL‐2 biomarkers
Study: 33766713
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant chemotherapy (no-NAC)
Study: 33204076
Drug: XueBiJing (XBJ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XueBiJing (XBJ) injection, 100 mL, q 12 h for 5-7 days
Study: 33139537
Drug: Subcutaneous BFKB8488A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous BFKB8488A injection
Study: 34417396
Drug: 40U DaxibotulinumtoxinA
Normalized name: daxibotulinumtoxinA-lanm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40U DaxibotulinumtoxinA (DAXI) treatment
Study: 35953872
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous cefazolin (1 g)
Study: 33340496
Drug: Inert auricular
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert auricular placebo patches
Study: 35104873
Drug: Analytical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analytical treatment interruptions (ATI)
Study: 33407719
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine plus ketamine (ketodex)
Study: 32687804
Drug: BPZE1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPZE1 vaccine (107, 108, and 109 CFU doses)
Study: 32687804
Drug: BPZE1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPZE1 vaccine (all doses)
Study: 32051822
Drug: 4 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 treatment sessions (group A)
Study: 32051822
Drug: 8 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 treatment sessions (group B)
Study: 32051822
Drug: 12 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 treatment sessions (group C)
Study: 35299115
Drug: Dietary carob
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary carob fruit (CF) supplementation (1 g/kg diet)
Study: 35299115
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 g/kg diet)
Study: 32320078
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CO2 laser treatment followed by three courses of oral traditional Chinese medicine)
Study: 32320078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CO2 laser treatment only)
Study: 32320078
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy group
Study: 35908167
Drug: Dexamethasone 24
Normalized name: dexAMETHasone 24 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 24 mg
Study: 33030703
Drug: Vericiguat 15
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vericiguat 15 mg (single dose)
Study: 33030703
Drug: Vericiguat 10
Normalized name: vericiguat 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 10 mg (once daily)
Study: 33030703
Drug: Vericiguat 2.5
Normalized name: vericiguat 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 2.5 mg (single or multiple doses)
Study: 34973039
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) plus pill placebo (PE+PLB)
Study: 34973039
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) plus sertraline (PE+SERT)
Study: 32537238
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care smoking cessation treatment (counseling and nicotine replacement therapy)
Study: 32369032
Drug: Prostate Cancer
Normalized name: Leuprolide Acetate 22.5mg Lyophilisate for suspension for injection [Prostate Cancer] with Diluent, Transfer Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate Cancer Screening Preparation (PCSPrep)
Study: 35090887
Drug: Electrical dry
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical dry needling plus corticosteroid injection (electrical-DN+CSI)
Study: 34557956
Drug: PBM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM therapy
Study: 35458131
Drug: Multi-Ingredient Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Ingredient Supplement (MS)
Study: 33537776
Drug: Lipopolysaccharide (LPS)
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipopolysaccharide (LPS) treatment (2.0 ng/kg)
Study: 34472596
Drug: aboBoNT‐A solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: aboBoNT‐A solution 50 U
Study: 35237893
Drug: Astaxanthin (AST)
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (AST) 8 mg daily for 40 days
Study: 34529963
Drug: MenACWY (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY (first dose) followed by placebo (second dose)
Study: 35501178
Drug: NVX-CoV2373 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1)
Study: 33164276
Drug: Emricasan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan (25 mg twice daily for 24 months)
Study: 33164276
Drug: Emricasan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan (25 mg twice daily for 24 months) in F3 to F5 subgroup
Study: 32191001
Drug: Low intensity-shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity-shockwave therapy (Li-ESWT), 6 sessions over three weeks
Study: 34899419
Drug: Gamified AACTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamified AACTP smartphone application + treatment as usual (TAU)
Study: 32894140
Drug: Isocaloric carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric carbohydrate supplements (CHO)
Study: 33037200
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid withdrawal
Study: 33307024
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group (invitation to primary colonoscopy and invitation for FIT for initial nonresponders)
Study: 34033935
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with 150 µM methylene blue for 2 minutes and a 660 nm wavelength laser for 3 minutes (100 mW, 600 J/cm², total 18J)
Study: 35878732
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g resistant starch (RS) daily
Study: 35468601
Drug: Brolucizumab 3
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brolucizumab 3 mg
Study: 33775019
Drug: Massage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage with sunflower oil (emollient therapy)
Study: 35934913
Drug: Hydroxyurea (1–2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (1–2 g d1–5) with cytarabine (1 g/m2/2 h b.i.d. d1–5) and daunorubicin (60 mg/m2 d1–3)
Study: 35934913
Drug: Hydroxyurea (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (1 g)
Study: 35934913
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo drug sensitivity assays
Study: 35934913
Drug: Hydroxyurea with
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea with standard chemotherapy
Study: 35867022
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion for 3 days after transplant
Study: 32351591
Drug: 8-week moderate-intensity
Normalized name: Rheumatrex Dose Pack 8, 4 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week moderate-intensity continuous aerobic exercise program with standard medical treatment
Study: 32351591
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment without any exercise program
Study: 36142070
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seeds (3 capsules daily, 2 in the morning and 1 in the evening)
Study: 36142070
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seeds (3 capsules every 12 hours)
Study: 36142070
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seeds (5 capsules in the morning and 4 in the evening)
Study: 36142070
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa powder (1 capsule every 12 hours)
Study: 36142070
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa powder (2 capsules every 12 hours)
Study: 36142070
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa powder (3 capsules every 12 hours)
Study: 36142070
Drug: Charcoal capsules
Normalized name: charcoal Oral Capsule
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoal capsules (control group)
Study: 33527863
Drug: Base ointment
Normalized name: Unibase Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base ointment (Eucerin) for daily wound dressing
Study: 34110925
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiation therapy (IFRT)
Study: 34110925
Drug: Posterior fossa
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior fossa radiation therapy (PFRT)
Study: 34110925
Drug: Low-dose craniospinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose craniospinal irradiation (LDCSI; 18 Gy)
Study: 34110925
Drug: Standard-dose craniospinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose craniospinal irradiation (SDCSI; 23.4 Gy)
Study: 34110925
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiation therapy (IFRT) in Sonic Hedgehog MB
Study: 34110925
Drug: Low-dose craniospinal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose craniospinal irradiation (LDCSI) in group 4 MB
Study: 34110925
Drug: Standard-dose craniospinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose craniospinal irradiation (SDCSI)
Study: 34528122
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus, 1 mg/kg infusion for first 30 min, followed by 0.5 mg/kg infusion for further 30 min)
Study: 34528122
Drug: NSAIDs (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (50 mg dexketoprofen trometamol and saline)
Study: 32385815
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (CA) treatment (5 mM) under Ni stress
Study: 32385815
Drug: Nickel (Ni)
DrugBank: Nickel sulfate (DB14180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nickel (Ni) treatment alone
Study: 32385815
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (CA) treatment under Ni stress
Study: 33025652
Drug: Potassium-sparing diuretics
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretics and aldosterone antagonists
Study: 33025652
Drug: Vasodilator antihypertensives
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator antihypertensives
Study: 32985036
Drug: Standard manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard manual therapy (MT)
Study: 610148118
Drug: Modern diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern diet (9217.6 kJ, macronutrient composition 331.7:66.1:76.9 g)
Study: 610148118
Drug: Traditional diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional diet (8807.3 kJ, macronutrient composition 364.3:30.1:66.4 g)
Study: 32181499
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of treatment (regression subgroup)
Study: 34225066
Drug: AIs alone
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIs alone (AI monotherapy)
Study: 33610954
Drug: Mandibular Advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular Advancement Splint (MAS) therapy
Study: 33290937
Drug: Cat adoption
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cat adoption (treatment group)
Study: 36291165
Drug: Intramuscular hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hypertonic saline solution (6%)
Study: 36291165
Drug: Intramuscular isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular isotonic saline solution (0.9%)
Study: 33079393
Drug: Education plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education plus exercise and physical therapy (LEAP)
Study: 33079393
Drug: Underwent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underwent chemotherapy
Study: 33410616
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg twice daily)
Study: 33410616
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg once daily)
Study: 36282186
Drug: Alirocumab (15–100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (15–100 mg)
Study: 36282186
Drug: Evolocumab (21–140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (21–140 mg)
Study: 34413142
Drug: Hyoscine N-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N-butylbromide (20 mg IV)
Study: 34413142
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg orally)
Study: 33821363
Drug: weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: weekly paclitaxel plus cetuximab (wPTX-Cmab)
Study: 34799380
Drug: Olaparib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (2 years of maintenance therapy)
Study: 33710371
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ULD-CT) with tin filtration (Sn140kV/50mAs)
Study: 33710371
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ULD-CT)
Study: 33710371
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ULD-CT) and Standard CT
Study: 32547310
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg orally for six months
Study: 33066812
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavioral therapy for insomnia (6 online sessions weekly + 2 face-to-face sessions)
Study: 33399016
Drug: Drug Adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Adjustment (DA)
Study: 34890827
Drug: Peanut Oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut Oral Immunotherapy (POIT) with a daily maintenance dose of 3,900 mg
Study: 34890827
Drug: Peanut Oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut Oral Immunotherapy (POIT) during maintenance
Study: 34890827
Drug: Peanut Oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut Oral Immunotherapy (POIT) after 1-month treatment discontinuation
Study: 34890827
Drug: Biomarker analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker analysis after 1-month discontinuation
Study: 35879013
Drug: App-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based treatment
Study: 34967805
Drug: Preincision local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincision local anesthetic injection
Study: 34967805
Drug: Postprocedure local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprocedure local anesthetic injection
Study: 32756520
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (morphine as primary analgesic)
Study: 34274044
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 25 mg/day
Study: 34349841
Drug: Oral vinorelbine-cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine-cisplatin (OV-CDDP) - 60–80 mg/m2 OV days 1 and 8 with 80 mg/m2 CDDP day 1
Study: 34349841
Drug: Gemcitabine-cisplatin (GEM-CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemcitabine-cisplatin (GEM-CDDP) - 1250 mg/m2 GEM days 1 and 8 with 75 mg/m2 CDDP day 1
Study: 35384398
Drug: 200-mg generic
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-mg generic pazopanib tablet
Study: 35384398
Drug: 200-mg branded
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mg branded pazopanib tablet
Study: 32930848
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg anthocyanins daily for 12 weeks
Study: 33023671
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma infusion (two bags of 238-337 ml each on day 1 and day 2)
Study: 33023671
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma infusion
Study: 32729819
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of memantine 10-mg tablet under fasting condition
Study: 32729819
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of memantine 10-mg tablet under fed condition
Study: 32729819
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Ebixa 10-mg tablet)
Study: 36181632
Drug: VOM ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VOM ethanol infusion
Study: 33704435
Drug: Vaccinated patients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated patients (received at least one dose of mRNA COVID-19 vaccine)
Study: 33704435
Drug: Unvaccinated patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unvaccinated patients (did not receive vaccine)
Study: 33704435
Drug: Vaccinated patients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated patients >10 days after 1st dose